-
Je něco špatně v tomto záznamu ?
The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus
P. Šimják, K. Anderlová, A. Cinkajzlová, A. Pařízek, M. Kršek, M. Haluzík
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, přehledy
- MeSH
- dospělí MeSH
- gestační diabetes etiologie patofyziologie MeSH
- lidé MeSH
- nemoci endokrinního systému komplikace patofyziologie MeSH
- těhotenství MeSH
- tuková tkáň patofyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Gestational diabetes mellitus (GDM) is diabetes that is first diagnosed in the second or third trimester of pregnancy in patients who did not have a history of diabetes before pregnancy. Consequences of GDM include increased risk of macrosomia and birth complications in the infant and an increased risk of maternal type 2 diabetes mellitus (T2DM) after pregnancy. There is also a longer-term risk of obesity, T2DM, and cardiovascular diseases in the child. GDM is the result of impaired glucose tolerance due to pancreatic β-cell dysfunction on a background of insulin resistance that physiologically increases during pregnancy. The strongest clinical predictors of GDM are overweight and obesity. The fact that women with GDM are more likely to be overweight or obese suggests that adipose tissue dysfunction may be involved in the pathogenesis of GDM, similarly to T2DM. Adipose tissue is not only involved in energy storage but also functions as an active endocrine organ secreting adipokines (specific hormones and cytokines) with the ability to alter insulin sensitivity. Recent evidence points to a crucial role of numerous adipokines produced by fat in the development of GDM. The following text summarizes the current knowledge about a possible role of selected adipokines in the development of GDM.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026592
- 003
- CZ-PrNML
- 005
- 20211026132800.0
- 007
- ta
- 008
- 211013s2020 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S0391-1977.20.03192-2 $2 doi
- 035 __
- $a (PubMed)33000620
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Šimják, Patrik $u Department of Gynecology and Obstetrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 245 14
- $a The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus / $c P. Šimják, K. Anderlová, A. Cinkajzlová, A. Pařízek, M. Kršek, M. Haluzík
- 520 9_
- $a Gestational diabetes mellitus (GDM) is diabetes that is first diagnosed in the second or third trimester of pregnancy in patients who did not have a history of diabetes before pregnancy. Consequences of GDM include increased risk of macrosomia and birth complications in the infant and an increased risk of maternal type 2 diabetes mellitus (T2DM) after pregnancy. There is also a longer-term risk of obesity, T2DM, and cardiovascular diseases in the child. GDM is the result of impaired glucose tolerance due to pancreatic β-cell dysfunction on a background of insulin resistance that physiologically increases during pregnancy. The strongest clinical predictors of GDM are overweight and obesity. The fact that women with GDM are more likely to be overweight or obese suggests that adipose tissue dysfunction may be involved in the pathogenesis of GDM, similarly to T2DM. Adipose tissue is not only involved in energy storage but also functions as an active endocrine organ secreting adipokines (specific hormones and cytokines) with the ability to alter insulin sensitivity. Recent evidence points to a crucial role of numerous adipokines produced by fat in the development of GDM. The following text summarizes the current knowledge about a possible role of selected adipokines in the development of GDM.
- 650 _2
- $a tuková tkáň $x patofyziologie $7 D000273
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a gestační diabetes $x etiologie $x patofyziologie $7 D016640
- 650 _2
- $a nemoci endokrinního systému $x komplikace $x patofyziologie $7 D004700
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těhotenství $7 D011247
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Anderlová, Kateřina $u Department of Gynecology and Obstetrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $u Third Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Cinkajzlová, Anna $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Pařízek, Antonín $u Department of Gynecology and Obstetrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Kršek, Michal $u Third Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Haluzík, Martin $u Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic - halm@ikem.cz
- 773 0_
- $w MED00184061 $t Minerva endocrinologica $x 1827-1634 $g Roč. 45, č. 3 (2020), s. 228-242
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33000620 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132807 $b ABA008
- 999 __
- $a ok $b bmc $g 1715350 $s 1147099
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 45 $c 3 $d 228-242 $e - $i 1827-1634 $m Minerva endocrinologica $n Minerva Endocrinol $x MED00184061
- LZP __
- $a Pubmed-20211013
